Literature DB >> 12411400

Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury.

Aesim Cho1, Michael A Reidy.   

Abstract

Matrix metalloproteinases (MMPs) and, in particular, MMP-9 are important for smooth muscle cell (SMC) migration into the intima. In this study, we sought to determine whether MMP-9 is critical for SMC migration and for the formation of a neointima by using mice in which the gene was deleted (MMP-9(-/-) mice). A denuding injury to the arteries of wild-type mice promoted the migration of medial SMCs into the neointima at 6 days, and a large neointimal lesion was observed after 28 days. In wild-type arteries, medial SMC replication was approximately 8% at day 4, 6% at day 6, and 4% at day 8 and had further decreased to 1% at day 14. Intimal cell replication was 65% at 8 days and had decreased to approximately 10% at 14 days after injury. In MMP-9(-/-) arteries, SMC replication was significantly lower at day 8. In addition, SMC migration and arterial lesion growth were significantly impaired in MMP-9(-/-) arteries. SMCs, isolated from MMP-9(-/-) mouse arteries, showed an impairment of migration and replication in vitro. Thus, our present data indicate that MMP-9 is critical for the development of arterial lesions by regulating both SMC migration and proliferation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411400     DOI: 10.1161/01.res.0000040420.17366.2e

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  92 in total

1.  Regulation of vascular smooth muscle cell growth: targeting the final common pathway.

Authors:  Angela M Taylor; Coleen A McNamara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-10-01       Impact factor: 8.311

2.  Sphingosine-1-phosphate receptor 3 promotes neointimal hyperplasia in mouse iliac-femoral arteries.

Authors:  Takuya Shimizu; Allison De Wispelaere; Martin Winkler; Travis D'Souza; Jacob Caylor; Lihua Chen; Frank Dastvan; Jessie Deou; Aesim Cho; Axel Larena-Avellaneda; Michael Reidy; Guenter Daum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-02-02       Impact factor: 8.311

3.  Toll-like receptors 4 induces expression of matrix metalloproteinase-9 in human aortic smooth muscle cells.

Authors:  Hongli Li; Hao Xu; Shaowen Liu
Journal:  Mol Biol Rep       Date:  2010-08-20       Impact factor: 2.316

Review 4.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 5.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

6.  Neovascularization and angiogenic gene expression following chronic arsenic exposure in mice.

Authors:  Nicole V Soucy; Debra Mayka; Linda R Klei; Antonia A Nemec; John A Bauer; Aaron Barchowsky
Journal:  Cardiovasc Toxicol       Date:  2005       Impact factor: 3.231

7.  Effect of matrix metalloproteinase-9 knockout on vein graft remodelling in mice.

Authors:  Anita C Thomas; Andrew C Newby
Journal:  J Vasc Res       Date:  2009-12-16       Impact factor: 1.934

8.  Resveratrol, wine, and atherosclerosis.

Authors:  Kailash Prasad
Journal:  Int J Angiol       Date:  2012-03

9.  The effect of matrix metalloproteinase 2 and matrix metalloproteinase 2/9 deletion in experimental post-thrombotic vein wall remodeling.

Authors:  Kristopher B Deatrick; Catherine E Luke; Megan A Elfline; Vikram Sood; Joseph Baldwin; Gilbert R Upchurch; Farouc A Jaffer; Thomas W Wakefield; Peter K Henke
Journal:  J Vasc Surg       Date:  2013-03-13       Impact factor: 4.268

10.  Sphingosine-1-phosphate receptor-2 regulates expression of smooth muscle alpha-actin after arterial injury.

Authors:  Allison D Grabski; Takuya Shimizu; Jessie Deou; William M Mahoney; Michael A Reidy; Guenter Daum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-16       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.